Analyst report says Buy

  1. 1,032 Posts.
    lightbulb Created with Sketch. 145
    BNO has posted a report by H C Wainright & Co. The report rates the stock as a buy. Big price target estimate is provided and speaks about the oncology assets as business development products with the focus ever increasingly turning to BNC210 (probably quite rightly so). It's worth a look. I guess the analyst's price target of $2 is going to make most holders happy. GLTA
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.